US Stock MarketDetailed Quotes

SCNI Scinai Immunotherapeutics

Watchlist
  • 3.261
  • +0.001+0.02%
Trading Dec 4 12:27 ET
2.78MMarket Cap1.36P/E (TTM)

Scinai Immunotherapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
8.28%-2.04M
68.34%-1.76M
-282.98%-1.46M
-29.14%-9.38M
-106.58%-1.23M
-16.82%-2.22M
-85.28%-5.55M
65.43%-382K
2.17%-7.27M
67.91%-593K
Net income from continuing operations
270.36%11.51M
38.28%-2.32M
38.58%-2.16M
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-1.63%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
Operating gains losses
--0
--3K
---96K
---4.14M
---216K
---591K
----
----
----
----
Depreciation and amortization
243.45%498K
237.41%496K
13.04%156K
-8.54%514K
-54.35%84K
46.46%145K
-34.40%147K
2.99%138K
19.32%562K
294.67%184K
Other non cash items
-196.55%-13.91M
-95.13%226K
169.66%225K
110.27%401K
-73.12%770K
32.50%-4.69M
1,308.71%4.64M
-236.29%-323K
-23.86%-3.9M
217.14%2.87M
Change In working capital
34.43%-280K
60.75%-303K
-43.44%220K
-393.73%-796K
-98.70%14K
-158.79%-427K
-256.66%-772K
-24.32%389K
-61.51%271K
220.64%1.08M
-Change in receivables
97.78%-2K
-19.70%-158K
6.43%149K
-307.14%-290K
-572.73%-208K
-373.68%-90K
-2,595.95%-132K
13.82%140K
137.29%140K
-67.94%44K
-Change in payables and accrued expense
17.26%-278K
77.43%-144K
-73.08%70K
-466.42%-491K
-78.45%223K
-128.57%-336K
40.85%-638K
-33.33%260K
-79.29%134K
338.88%1.04M
-Change in other current assets
2,750.00%57K
5,600.00%114K
516.67%75K
-71.90%43K
-65.03%57K
--2K
--2K
-128.57%-18K
3.38%153K
--163K
-Change in other current liabilities
-1,800.00%-57K
-2,775.00%-115K
-1,157.14%-74K
62.82%-58K
65.06%-58K
-400.00%-3K
-100.25%-4K
111.29%7K
-4.00%-156K
88.25%-166K
Cash from discontinued investing activities
Operating cash flow
8.28%-2.04M
38.87%-1.76M
52.17%-1.46M
-29.14%-9.38M
-106.58%-1.23M
-16.82%-2.22M
4.04%-2.88M
-176.83%-3.06M
2.17%-7.27M
67.91%-593K
Investing cash flow
Cash flow from continuing investing activities
80.00%-4K
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-1,458.29%-377K
98.85%-6K
-501.44%-836K
-153.78%-270K
Net PPE purchase and sale
80.00%-4K
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-2,874.92%-377K
98.85%-6K
-501.44%-836K
-175.49%-270K
Cash from discontinued investing activities
Investing cash flow
80.00%-4K
98.41%-6K
66.67%-2K
23.80%-637K
13.33%-234K
75.00%-20K
-1,458.29%-377K
98.85%-6K
-501.44%-836K
-153.78%-270K
Financing cash flow
Cash flow from continuing financing activities
-99.26%8K
12K
1.42M
-83.97%1.09M
0
1.09M
0
0
-68.38%6.78M
-23.41%6.78M
Net common stock issuance
----
----
----
-85.09%139K
----
----
----
----
-95.65%932K
----
Proceeds from stock option exercised by employees
-99.26%8K
--12K
--1.42M
-83.80%947K
-102.38%-139K
--1.09M
--0
--0
--5.84M
--5.84M
Cash from discontinued financing activities
Financing cash flow
-99.26%8K
--12K
--1.42M
-83.97%1.09M
--0
--1.09M
--0
--0
-68.38%6.78M
-23.41%6.78M
Net cash flow
Beginning cash position
-57.89%3.21M
-54.55%4.97M
-64.76%5.01M
-18.85%14.22M
-23.24%6.48M
-33.19%7.63M
-22.40%10.93M
-18.85%14.22M
469.29%17.52M
-21.55%8.45M
Current changes in cash
-65.63%-1.91M
42.42%-1.87M
98.56%-44K
-574.19%-8.93M
-124.66%-1.46M
41.93%-1.16M
-3.07%-3.25M
-88.50%-3.07M
-109.56%-1.33M
-14.11%5.92M
Effect of exchange rate changes
-1,985.71%-132K
395.12%121K
--0
86.24%-272K
90.73%-14K
100.71%7K
-109.06%-41K
37.60%-224K
-443.83%-1.98M
48.68%-151K
End cash Position
-81.97%1.17M
-57.89%3.21M
-54.55%4.97M
-64.76%5.01M
-64.76%5.01M
-23.24%6.48M
-32.91%7.63M
-29.65%10.93M
-18.85%14.22M
-18.85%14.22M
Free cash flow
8.92%-2.04M
45.77%-1.76M
52.20%-1.47M
-23.68%-10.02M
-69.06%-1.46M
-13.12%-2.24M
-8.08%-3.25M
-88.50%-3.07M
-7.09%-8.1M
55.66%-863K
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 8.28%-2.04M68.34%-1.76M-282.98%-1.46M-29.14%-9.38M-106.58%-1.23M-16.82%-2.22M-85.28%-5.55M65.43%-382K2.17%-7.27M67.91%-593K
Net income from continuing operations 270.36%11.51M38.28%-2.32M38.58%-2.16M-12.15%-6.5M54.46%-2.33M-34.97%3.11M-1.63%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M
Operating gains losses --0--3K---96K---4.14M---216K---591K----------------
Depreciation and amortization 243.45%498K237.41%496K13.04%156K-8.54%514K-54.35%84K46.46%145K-34.40%147K2.99%138K19.32%562K294.67%184K
Other non cash items -196.55%-13.91M-95.13%226K169.66%225K110.27%401K-73.12%770K32.50%-4.69M1,308.71%4.64M-236.29%-323K-23.86%-3.9M217.14%2.87M
Change In working capital 34.43%-280K60.75%-303K-43.44%220K-393.73%-796K-98.70%14K-158.79%-427K-256.66%-772K-24.32%389K-61.51%271K220.64%1.08M
-Change in receivables 97.78%-2K-19.70%-158K6.43%149K-307.14%-290K-572.73%-208K-373.68%-90K-2,595.95%-132K13.82%140K137.29%140K-67.94%44K
-Change in payables and accrued expense 17.26%-278K77.43%-144K-73.08%70K-466.42%-491K-78.45%223K-128.57%-336K40.85%-638K-33.33%260K-79.29%134K338.88%1.04M
-Change in other current assets 2,750.00%57K5,600.00%114K516.67%75K-71.90%43K-65.03%57K--2K--2K-128.57%-18K3.38%153K--163K
-Change in other current liabilities -1,800.00%-57K-2,775.00%-115K-1,157.14%-74K62.82%-58K65.06%-58K-400.00%-3K-100.25%-4K111.29%7K-4.00%-156K88.25%-166K
Cash from discontinued investing activities
Operating cash flow 8.28%-2.04M38.87%-1.76M52.17%-1.46M-29.14%-9.38M-106.58%-1.23M-16.82%-2.22M4.04%-2.88M-176.83%-3.06M2.17%-7.27M67.91%-593K
Investing cash flow
Cash flow from continuing investing activities 80.00%-4K98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-1,458.29%-377K98.85%-6K-501.44%-836K-153.78%-270K
Net PPE purchase and sale 80.00%-4K98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-2,874.92%-377K98.85%-6K-501.44%-836K-175.49%-270K
Cash from discontinued investing activities
Investing cash flow 80.00%-4K98.41%-6K66.67%-2K23.80%-637K13.33%-234K75.00%-20K-1,458.29%-377K98.85%-6K-501.44%-836K-153.78%-270K
Financing cash flow
Cash flow from continuing financing activities -99.26%8K12K1.42M-83.97%1.09M01.09M00-68.38%6.78M-23.41%6.78M
Net common stock issuance -------------85.09%139K-----------------95.65%932K----
Proceeds from stock option exercised by employees -99.26%8K--12K--1.42M-83.80%947K-102.38%-139K--1.09M--0--0--5.84M--5.84M
Cash from discontinued financing activities
Financing cash flow -99.26%8K--12K--1.42M-83.97%1.09M--0--1.09M--0--0-68.38%6.78M-23.41%6.78M
Net cash flow
Beginning cash position -57.89%3.21M-54.55%4.97M-64.76%5.01M-18.85%14.22M-23.24%6.48M-33.19%7.63M-22.40%10.93M-18.85%14.22M469.29%17.52M-21.55%8.45M
Current changes in cash -65.63%-1.91M42.42%-1.87M98.56%-44K-574.19%-8.93M-124.66%-1.46M41.93%-1.16M-3.07%-3.25M-88.50%-3.07M-109.56%-1.33M-14.11%5.92M
Effect of exchange rate changes -1,985.71%-132K395.12%121K--086.24%-272K90.73%-14K100.71%7K-109.06%-41K37.60%-224K-443.83%-1.98M48.68%-151K
End cash Position -81.97%1.17M-57.89%3.21M-54.55%4.97M-64.76%5.01M-64.76%5.01M-23.24%6.48M-32.91%7.63M-29.65%10.93M-18.85%14.22M-18.85%14.22M
Free cash flow 8.92%-2.04M45.77%-1.76M52.20%-1.47M-23.68%-10.02M-69.06%-1.46M-13.12%-2.24M-8.08%-3.25M-88.50%-3.07M-7.09%-8.1M55.66%-863K
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data